drugset / Trial / NCT04557020
Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized clinical trial comparing neoadjuvant and adjuvant PD-1 inhibitor Toripalimab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy alone in high-risk nasopharyngeal carcinoma
Timeline
- Start
- 2020-12-30
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |